Brentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin's lymphoma
-
Published:2019-06-29
Issue:2
Volume:18
Page:83-91
-
ISSN:2414-9314
-
Container-title:Pediatric Hematology/Oncology and Immunopathology
-
language:
-
Short-container-title:Voprosy gematologii/onkologii i immunopatologii v pediatrii
Author:
Kozlov A. V.1ORCID, Kazantzev I. V.1ORCID, Iukhta T. V.1ORCID, Tolkunova P. S.1ORCID, Gevorgian A. G.1ORCID, Lepik K. V.1ORCID, Borzenkova E. S.1ORCID, Zaljalov Yu. R.1ORCID, Botina A. V.1ORCID, Baikov V. V.1ORCID, Morozova E. V.1ORCID, Mikhailova N. B.1ORCID, Zubarovskaya L. S.1ORCID, Afanasyev B. V.1ORCID
Affiliation:
1. Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of Saint-Petersburg
Abstract
Children and adolescents with refractory or relapsed Hodgkin's lymphoma (R-R HL) have unfavorable prognosis if ≥ 3 lines of therapies have to be used. New strategies based on innovative approaches are crucial for this group of patients. Nowadays immunotherapy for oncological diseases is the most promising and actively developing area. Brentuximab vedotin (BV) is efficient in adults with HL. Data in children are limited to pilot studies that are focused on response to treatment without analysis of survival. The present study demonstrates experience of Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation (First Pavlov State Medical University of Saint-Petersburg) in the management of heavily pretreated (median number of prior lines – 4) children and adolescents with R-R HL. The study was approved by the Independent Ethics Committee of the Raisa Gorbacheva Memorial Research Institute of Children's Oncology, Hematology and Transplantation. Brentuximab vedotin was administered to 34 patients. Overall response was achieved in 71% (complete response – 29%, partial response – 42%). Long-term progression free and overall survival were 24 and 54%, respectively.
Publisher
Fund Doctors, Innovations, Science for Children
Subject
Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health
Reference30 articles.
1. Harris R.E., Termuhlen A.M., Smith L.M., Lynch J., Henry M.M., Perkins S.L., et al. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962. Biol Blood Marrow Transplant 2011 Feb; 17 (2): 249–58. 2. Schellong G., Dorffel W., Claviez A., Körholz D., Mann G., Scheel-Walter H.G., et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181–9. 3. Giulino-Roth L., O'Donohue T., Chen Z., Trippett T.M., Klein E., Kernan N.A., et al. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma 2017 Nov; 29: 1–10. 4. Satwani P., Ahn K.W., Carreras J., Abdel-Azim H., Cairo M.S., Cashen A., et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 2015; 50: 1416–23. 5. Kulichkina N.S., Belyaeva E.S., Mentkevich G.L., Boyarshinov V.K., Levashov A.S., Glekov I.V., Popa A.V. Lechenie retsidivov i refrakternykh form limfomy Khodzhkina u detei. Klinicheskaya onkogematologiya 2016; 9 (1): 13–21.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|